High STAT1 mRNA levels but not its tyrosine phosphorylation are associated with macrophage infiltration and bad prognosis in breast cancer

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Tymoszuk, Piotr ^a   Charoentong, Pornpimol ^a   Hackl, Hubert ^a   Spilka, Rita ^b   Müller Holzner, Elisabeth ^a   Trajanoski, Zlatko ^a   Obrist, Peter ^b   Revillion, Françoise ^c   Peyrat, Jean Philippe ^c   Fiegl, Heidi ^a   Doppler, Wolfgang ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b St Vinzenz Hospital   (Austria)

^c CENTRE OSCAR LAMBRET   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD163 ANTIGEN; CD45 ANTIGEN; CD68 ANTIGEN; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERFERON REGULATORY FACTOR 1; MESSENGER RNA; PROGRAMMED DEATH 1 RECEPTOR; SERINE; STAT1 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; TRANSCRIPTION FACTOR FOXP3; TYROSINE; STAT1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER PROGNOSIS; CANCER TISSUE; CD163 GENE; CD45 GENE; CELL INFILTRATION; COHORT ANALYSIS; CONTROLLED STUDY; CXCL10 GENE; CXCL11 GENE; CXCL9 GENE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOXP3 GENE; GAMMA INTERFERON GENE; GENE; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IFIT1 GENE; IFITM1 GENE; IMMUNOBLOTTING; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IRF1 GENE; MACROPHAGE; MAJOR CLINICAL STUDY; MX1 GENE; PD 1 GENE; PD L1 GENE; PD L2 GENE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOCS1 GENE; STAT1 GENE; TUMOR ASSOCIATED LEUKOCYTE; BIOSYNTHESIS; BREAST TUMOR; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; PROGNOSIS; SIGNAL TRANSDUCTION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; PHOSPHORYLATION; PROGNOSIS; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; TYROSINE;

EID: 84899472350     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-257     Document Type: Article

References (56)

1. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006, 6(11):836-848. 10.1038/nri1961, 17063185.
2. Saha B, Jyothi Prasanna S, Chandrasekar B, Nandi D. Gene modulation and immunoregulatory roles of interferon gamma. Cytokine 2010, 50(1):1-14. 10.1016/j.cyto.2009.11.021, 20036577.
3. Ramana CV, Gil MP, Schreiber RD, Stark GR. Stat1-dependent and -independent pathways in IFN-gamma-dependent signaling. Trends Immunol 2002, 23(2):96-101. 10.1016/S1471-4906(01)02118-4, 11929133.
4. Najjar I, Fagard R. STAT1 and pathogens, not a friendly relationship. Biochimie 2010, 92(5):425-444. 10.1016/j.biochi.2010.02.009, 20159032.
5. Datta S, Parajuli N, Tymoszuk P, Ottina E, Parson W, Sgonc R, Villunger A, Doppler W. Replenishment of the B cell compartment after doxorubicin-induced hematopoietic toxicity is facilitated by STAT1. J Leukoc Biol 2013, (in press).
6. Barbi J, Snider HM, Bhardwaj N, Lezama-Davila CM, Durbin JE, Satoskar AR. Signal transducer and activator of transcription 1 in T cells plays an indispensable role in immunity to Leishmania major by mediating Th1 cell homing to the site of infection. FASEB J 2009, 23(11):3990-3999. 10.1096/fj.09-138057, 2775013, 19641143.
7. Quigley M, Huang X, Yang Y. STAT1 signaling in CD8 T cells is required for their clonal expansion and memory formation following viral infection in vivo. J Immunol 2008, 180(4):2158-2164. 10.4049/jimmunol.180.4.2158, 18250422.
8. Klover PJ, Muller WJ, Robinson GW, Pfeiffer RM, Yamaji D, Hennighausen L. Loss of STAT1 from mouse mammary epithelium results in an increased neu-induced tumor burden. Neoplasia 2010, 12(11):899-905. 2978912, 21076615.
9. Raven JF, Williams V, Wang S, Tremblay ML, Muller WJ, Durbin JE, Koromilas AE. Stat1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation. Cell Cycle 2011, 10(5):794-804. 10.4161/cc.10.5.14956, 21311224.
10. Kim HS, Lee MS. STAT1 as a key modulator of cell death. Cell Signal 2007, 19(3):454-465. 10.1016/j.cellsig.2006.09.003, 17085014.
11. Hannesdottir L, Tymoszuk P, Parajuli N, Wasmer MH, Philipp S, Daschil N, Datta S, Koller JB, Tripp CH, Stoitzner P, Muller-Holzner E, Wiegers GJ, Sexl V, Villunger A, Doppler W. Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response. Eur J Immunol 2013, 43(10):2718-2729. 10.1002/eji.201242505, 23843024.
12. Schneckenleithner C, Bago-Horvath Z, Dolznig H, Neugebauer N, Kollmann K, Kolbe T, Decker T, Kerjaschki D, Wagner KU, Muller M, Stoiber D, Sexl V. Putting the brakes on mammary tumorigenesis: Loss of STAT1 predisposes to intraepithelial neoplasias. Oncotarget 2011, 2(12):1043-1054. 3282066, 22185785.
13. Koromilas AE, Sexl V. The tumor suppressor function of STAT1 in breast cancer. JAKSTAT 2013, 2(2):e23353. 3710319, 24058806.
14. Chan SR, Vermi W, Luo J, Lucini L, Rickert C, Fowler AM, Lonardi S, Arthur C, Young LJ, Levy DE, Welch MJ, Cardiff RD, Schreiber RD. STAT1-deficient mice spontaneously develop estrogen receptor alpha-positive luminal mammary carcinomas. Breast Cancer Res 2012, 14(1):R16. 10.1186/bcr3100, 3496133, 22264274.
15. Efimova EV, Liang H, Pitroda SP, Labay E, Darga TE, Levina V, Lokshin A, Roizman B, Weichselbaum RR, Khodarev NN. Radioresistance of Stat1 over-expressing tumour cells is associated with suppressed apoptotic response to cytotoxic agents and increased IL6-IL8 signalling. Int J Radiat Biol 2009, 85(5):421-431. 10.1080/09553000902838566, 2690884, 19437244.
16. Khodarev NN, Roach P, Pitroda SP, Golden DW, Bhayani M, Shao MY, Darga TE, Beveridge MG, Sood RF, Sutton HG, Beckett MA, Mauceri HJ, Posner MC, Weichselbaum RR. STAT1 pathway mediates amplification of metastatic potential and resistance to therapy. PLoS ONE 2009, 4(6):e5821. 10.1371/journal.pone.0005821, 2688034, 19503789.
17. Weichselbaum RR, Ishwaran H, Yoon T, Nuyten DS, Baker SW, Khodarev N, Su AW, Shaikh AY, Roach P, Kreike B, Roizman B, Bergh J, Pawitan Y, van de Vijver MJ, Minn AJ. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci U S A 2008, 105(47):18490-18495. 10.1073/pnas.0809242105, 2587578, 19001271.
18. Hix LM, Karavitis J, Khan MW, Shi YH, Khazaie K, Zhang M. Tumor STAT1 transcription factor activity enhances breast tumor growth and immune suppression mediated by myeloid-derived suppressor cells. J Biol Chem 2013, 288(17):11676-11688.
19. Khodarev NN, Roizman B, Weichselbaum RR. Molecular pathways: interferon/stat1 pathway: role in the tumor resistance to genotoxic stress and aggressive growth. Clin Cancer Res 2012, 18(11):3015-3021. 10.1158/1078-0432.CCR-11-3225, 22615451.
20. Widschwendter A, Tonko-Geymayer S, Welte T, Daxenbichler G, Marth C, Doppler W. Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer. Clin Cancer Res 2002, 8(10):3065-3074.
21. DeNardo DG, Coussens LM. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 2007, 9(4):212. 10.1186/bcr1746, 2206719, 17705880.
22. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirstrom K, West BL, Coussens LM. Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy. Cancer Discov 2011, 1:54-67. 10.1158/2159-8274.CD-10-0028, 3203524, 22039576.
23. King KY, Goodell MA. Inflammatory modulation of HSCs: viewing the HSC as a foundation for the immune response. Nat Rev Immunol 2011, 11(10):685-692. 10.1038/nri3062, 21904387.
24. Marth C, Fiegl H, Zeimet AG, Muller-Holzner E, Deibl M, Doppler W, Daxenbichler G. Interferon-gamma expression is an independent prognostic factor in ovarian cancer. Am J Obstet Gynecol 2004, 191(5):1598-1605. 10.1016/j.ajog.2004.05.007, 15547530.
25. Haffner MC, Petridou B, Peyrat JP, Revillion F, Muller-Holzner E, Daxenbichler G, Marth C, Doppler W. Favorable prognostic value of SOCS2 and IGF-I in breast cancer. BMC Cancer 2007, 7:136. 10.1186/1471-2407-7-136, 1948006, 17651480.
26. Berlato C, Doppler W. Selective response to insulin versus insulin-like growth factor-I and -II and up-regulation of insulin receptor splice variant B in the differentiated mouse mammary epithelium. Endocrinology 2009, 150(6):2924-2933. 10.1210/en.2008-0668, 19246539.
27. Sturn A, Quackenbush J, Trajanoski Z. Genesis: cluster analysis of microarray data. Bioinformatics 2002, 18(1):207-208. 10.1093/bioinformatics/18.1.207, 11836235.
28. Zuo T, Wang L, Morrison C, Chang X, Zhang H, Li W, Liu Y, Wang Y, Liu X, Chan MW, Liu JQ, Love R, Liu CG, Godfrey V, Shen R, Huang TH, Yang T, Park BK, Wang CY, Zheng P. FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell 2007, 129(7):1275-1286. 10.1016/j.cell.2007.04.034, 1974845, 17570480.
29. Droeser RA, Obermann EC, Wolf AM, Wallner S, Wolf D, Tzankov A. Negligible nuclear FOXP3 expression in breast cancer epithelial cells compared with FOXP3-positive T cells. Clin Breast Cancer 2013, 13(4):264-270. 10.1016/j.clbc.2013.02.009, 23829892.
30. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012, 12(4):252-264. 10.1038/nrc3239, 22437870.
31. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012, 24(2):207-212. 10.1016/j.coi.2011.12.009, 3319479, 22236695.
32. Rozali EN, Hato SV, Robinson BW, Lake RA, Lesterhuis WJ. Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol 2012, 2012:656340. 3350956, 22611421.
33. Noguchi A, Watanabe K, Narumi S, Yamagami H, Fujiwara Y, Higuchi K, Oshitani N, Arakawa T. The production of interferon-gamma-inducible protein 10 by granulocytes and monocytes is associated with ulcerative colitis disease activity. J Gastroenterol 2007, 42(12):947-956. 10.1007/s00535-007-2118-9, 18085351.
34. Takada H, Takahata Y, Nomura A, Ohga S, Mizuno Y, Hara T. Increased serum levels of interferon-gamma-inducible protein 10 and monokine induced by gamma interferon in patients with haemophagocytic lymphohistiocytosis. Clin Exp Immunol 2003, 133(3):448-453. 10.1046/j.1365-2249.2003.02237.x, 1808805, 12930373.
35. Itoh Y, Morita A, Nishioji K, Narumi S, Toyama T, Daimon Y, Nakamura H, Kirishima T, Okanoue T. Clinical significance of elevated serum interferon- inducible protein-10 levels in hepatitis C virus carriers with persistently normal serum transaminase levels. J Viral Hepat 2001, 8(5):341-348. 10.1046/j.1365-2893.2001.00309.x, 11555191.
36. Lee EY, Lee ZH, Song YW. CXCL10 and autoimmune diseases. Autoimmun Rev 2009, 8(5):379-383. 10.1016/j.autrev.2008.12.002, 19105984.
37. Casrouge A, Decalf J, Ahloulay M, Lababidi C, Mansour H, Vallet-Pichard A, Mallet V, Mottez E, Mapes J, Fontanet A, Pol S, Albert ML. Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J Clin Invest 2011, 121(1):308-317. 10.1172/JCI40594, 3007131, 21183794.
38. Zimmerman MA, Rahman NT, Yang D, Lahat G, Lazar AJ, Pollock RE, Lev D, Liu K. Unphosphorylated STAT1 promotes sarcoma development through repressing expression of Fas and bad and conferring apoptotic resistance. Cancer Res 2012, 72(18):4724-4732. 10.1158/0008-5472.CAN-12-1347, 3564959, 22805310.
39. Heinonen KM, Bourdeau A, Doody KM, Tremblay ML. Protein tyrosine phosphatases PTP-1B and TC-PTP play nonredundant roles in macrophage development and IFN-{gamma} signaling. Proc Natl Acad Sci U S A 2009, 106(23):9368-9372. 10.1073/pnas.0812109106, 2695062, 19474293.
40. Haspel RL, Salditt-Georgieff M, Darnell JE. The rapid inactivation of nuclear tyrosine phosphorylated Stat1 depends upon a protein tyrosine phosphatase. EMBO J 1996, 15(22):6262-6268. 452449, 8947049.
41. Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 2007, 7(6):454-465. 10.1038/nri2093, 17525754.
42. Levy DE, Darnell JE. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002, 3(9):651-662. 10.1038/nrm909, 12209125.
43. Cheon H, Stark GR. Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes. Proc Natl Acad Sci U S A 2009, 106(23):9373-9378. 10.1073/pnas.0903487106, 2688000, 19478064.
44. Cheon H, Yang J, Stark GR. The functions of signal transducers and activators of transcriptions 1 and 3 as cytokine-inducible proteins. J Interferon Cytokine Res 2011, 31(1):33-40. 10.1089/jir.2010.0100, 3021352, 21166594.
45. Decker T, Kovarik P. Serine phosphorylation of STATs. Oncogene 2000, 19(21):2628-2637. 10.1038/sj.onc.1203481, 10851062.
46. Bancerek J, Poss ZC, Steinparzer I, Sedlyarov V, Pfaffenwimmer T, Mikulic I, Dolken L, Strobl B, Muller M, Taatjes DJ, Kovarik P. CDK8 kinase phosphorylates transcription factor STAT1 to selectively regulate the interferon response. Immunity 2013, 38(2):250-262. 10.1016/j.immuni.2012.10.017, 3580287, 23352233.
47. Putz EM, Gotthardt D, Hoermann G, Csiszar A, Wirth S, Berger A, Straka E, Rigler D, Wallner B, Jamieson AM, Pickl WF, Zebedin-Brandl EM, Muller M, Decker T, Sexl V. CDK8-mediated STAT1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance. Cell Rep 2013, 4(3):437-444. 10.1016/j.celrep.2013.07.012, 3748339, 23933255.
48. Barnholt KE, Kota RS, Aung HH, Rutledge JC. Adenosine blocks IFN-gamma-induced phosphorylation of STAT1 on serine 727 to reduce macrophage activation. J Immunol 2009, 183(10):6767-6777. 10.4049/jimmunol.0900331, 2916018, 19846878.
49. Pierce BL, Neuhouser ML, Wener MH, Bernstein L, Baumgartner RN, Ballard-Barbash R, Gilliland FD, Baumgartner KB, Sorensen B, McTiernan A, Ulrich CM. Correlates of circulating C-reactive protein and serum amyloid A concentrations in breast cancer survivors. Breast Cancer Res Treat 2009, 114(1):155-167. 10.1007/s10549-008-9985-5, 3523176, 18401703.
50. Wisskirchen C, Ludersdorfer TH, Muller DA, Moritz E, Pavlovic J. Interferon-induced antiviral protein MxA interacts with the cellular RNA helicases UAP56 and URH49. J Biol Chem 2011, 286(40):34743-34751. 3186362, 21859714.
51. Datta D, Flaxenburg JA, Laxmanan S, Geehan C, Grimm M, Waaga-Gasser AM, Briscoe DM, Pal S. Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer. Cancer Res 2006, 66(19):9509-9518. 10.1158/0008-5472.CAN-05-4345, 17018607.
52. Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM. Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A 2012, 109(8):2796-2801. 10.1073/pnas.1104303108, 3287000, 21825174.
53. Medrek C, Ponten F, Jirstrom K, Leandersson K. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer 2012, 12:306. 10.1186/1471-2407-12-306, 3414782, 22824040.
54. Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, Von Torne C, Weichert W, Engels K, Solbach C, Schrader I, Dietel M, Von Minckwitz G. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010, 28(1):105-113. 10.1200/JCO.2009.23.7370, 19917869.
55. West NR, Milne K, Truong PT, Macpherson N, Nelson BH, Watson PH. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res 2011, 13(6):R126. 10.1186/bcr3072, 3326568, 22151962.
56. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, Ellis IO, Green AR. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011, 29(15):1949-1955. 10.1200/JCO.2010.30.5037, 21483002.